Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.55 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.54 |
| ▸ | JAK2 | O60674 | 3/20 | 0.54 |
| ▸ | JAK1 | P23458 | 3/20 | 0.54 |
| ▸ | TYK2 | P29597 | 3/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL912991 | 0.96 | JAK3 (0.53) | JAK3GABRG2GABRB3GABRA5IRAK4 | |
| SCHEMBL912989 | 0.84 | JAK3 (0.78) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL914067 | 0.84 | JAK3 (0.56) | JAK3GABRG2GABRB3GABRA5IRAK4 | |
| SCHEMBL915068 | 0.84 | JAK3 (0.60) | JAK3GABRG2GABRB3GABRA5IRAK4 | |
| SCHEMBL913762 | 0.83 | SYK (0.60) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL914732 | 0.83 | JAK3 (0.54) | JAK3GABRG2GABRB3GABRA5IRAK4 | |
| SCHEMBL17452160 | 0.82 | JAK3 (0.55) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL913304 | 0.82 | JAK3 (0.64) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL913048 | 0.82 | JAK3 (0.64) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL2695381 | 0.82 | JAK3 (0.55) | JAK3GABRG2GABRB3GABRA5IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | claimed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | claimed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | JAK3 3/4885GABRG2 1357/4885GABRB3 1702/4885 |
| US-20110005947-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | JAK3 3/4885GABRG2 1357/4885GABRB3 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.